慢性掌跖脓疱病干预措施:Cochrane系统综述简版与GRADE评估
该Cochrane系统综述纳入37项RCT(1663例患者),评估慢性掌跖脓疱病(PPP)干预措施诱导和维持完全缓解的效果。局部维生素D衍生物可能优于安慰剂达到清除;生物制剂中古塞奇尤单抗和司库奇尤单抗可能减轻疾病严重度但可能增加严重不良事件。主要慢性PPP治疗证据缺乏,偏倚风险和不精确性限制结论可靠性。
要点
- 局部维生素D衍生物可能优于安慰剂达到清除(低确定性证据)。
- 古塞奇尤单抗和司库奇尤单抗可能减轻严重度但可能增加严重不良事件。
- 主要慢性PPP治疗证据缺乏,偏倚风险和不精确性限制结论可靠性。
核心结论
- 主要慢性PPP治疗缺乏支持或反对的证据,偏倚风险和不精确性限制结果可靠性。
研究设计与样本
- Cochrane系统综述纳入37项RCT,共1663例PPP或慢性掌跖脓疱型银屑病患者,76%为女性,平均年龄50岁,平均治疗 duration 11周。
主要发现
- 依那西普与安慰剂达到清除方面 little or no difference(低确定性证据,来自一项试验)。
- 乌司奴单抗在减轻严重度方面劣于安慰剂(低确定性证据,来自一项试验)。
局限性
- 偏倚风险和不精确性限制对结果的信心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Palmoplantar pustulosis (PPP) is a chronic inflammatory disease in which sterile and relapsing pustules appear on the palms and soles. OBJECTIVES: To assess the effects of interventions for chronic PPP to induce and maintain complete remission. METHODS: We searched for randomized controlled trials (RCTs), including people with PPP or chronic palmoplantar pustular psoriasis, in the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS and eight trials registers up to July 2020. Study selection, data extraction and risk-of-bias assessment were carried out independently by two review authors. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method. RESULTS: We included 37 RCTs (1663 participants, 76% women, mean age 50 years). Mean treatment duration was 11 weeks. Topical vitamin D derivative may be more effective than placebo in achieving clearance [risk ratio (RR) 7·83, 95% confidence interval (CI) 1·85-33·12; low-certainty evidence from two trials]. Concerning biological therapies, there was little or no difference between etanercept and placebo in achieving clearance (low-certainty evidence from one trial), ustekinumab is less effective than placebo in reducing severity (low-certainty evidence from one trial), and guselkumab (RR 2·88, 95% CI 1·24-6·69) and secukinumab (RR 1·55, 95% CI 1·02-2·35) are probably better in reducing disease severity (moderate-certainty evidence from two and one trial(s), respectively) but may cause more serious adverse events than placebo. CONCLUSIONS: Evidence is lacking for or against major chronic PPP treatments. Risk of bias and imprecision limit our confidence in the results.
引用
- Obeid G, Do G, Kirby L, et al. Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments. Br J Dermatol. 2020. PMID: 32961599. doi:10.1111/bjd.19560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。